Malaria Vaccine Efficacy Varies by Subgroups and Is of Limited Duration

Vaccine efficacy was lowest in areas with high transmission intensity and, 3 years after vaccination, had declined to zero.

Early results of phase III trials of the RTS,S/AS01 malaria vaccine show partial protection for 12 months after vaccination (JW Infect Dis Nov 28 2012); full results are expected in 2015. Now, investigators have analyzed pooled data from seven phase IIb trials in which RTS,S was given with AS01 or AS02 adjuvant (11 sites in 6 African countries; 4453 participants) to assess factors that affect vaccine efficacy. Transmission intensity was defined using estimated local prevalence of asymptomatic parasitemia in children aged 2 to 10 years. Endpoints were infection, clinical malaria, severe malaria, and death.

Vaccine efficacy against first and all episodes of clinical malaria varied by local transmission intensity. Efficacy against all episodes …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine